Drug intelligence / Profile preview

EBNK-1822H2

Development stage: Phase 2
Lead developer: Beijing Biotech
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

EBNK-1822H2 is an allogeneic, cord blood-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech. It is engineered to simultaneously target two tumor-associated antigens: Claudin 18.2 (CLDN18.2) and Human Epidermal Growth Factor Receptor 2 (HER2). This dual-targeting approach is designed to enhance anti-tumor activity and mitigate antigen escape in solid tumors, specifically esophageal adenocarcinoma. As an allogeneic product, it is intended for off-the-shelf use. The therapy is currently being evaluated in Phase 1/2 clinical trials for patients with relapsed, refractory, or metastatic esophageal adenocarcinoma.

Other names: EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells

Targets

Claudin 18.2ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on EBNK-1822H2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBNK-1822H2.

Explore the full profile